Boston Scientific Corporation (BSX) Earnings

Boston Scientific Corporation

BSX · NYSE

Sep 2026upcoming

Next quarter

Consensus is $0.80 EPS for Sep 2026 across 8 estimates, ranging $0.79 to $0.81.

BSX Jun 2026

Reported Jul 29, 2026

Beat 3.61%

EPS estimate: $0.83
EPS actual: $0.86
Revenue estimate: —
Revenue actual: —
1-day move: -0.09%

Call highlights have not been generated for this quarter.

Symbol: BSX
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NYSE

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Key Issues

Bullish view

Management highlighted future product catalysts, suggesting newer offerings can sustain growth even as WATCHMAN faces pressure. Second-quarter revenue reached the high end of guidance, supporting the demand case.

Bearish view

WATCHMAN pressure was substantial enough to feature in management’s outlook reduction. Electrophysiology pressure adds another area of uncertainty, making the timing and scale of replacement growth unclear.

Analyst Consensus

See all

Buy

25 analysts

$47

Current

—

Low

$60

Average

—

High

Average target implies +27.05% versus the current price.

Earnings History

BeatMissNo estimate

Peers

The Cigna GroupCI · NYSE$271.10